knowledge -WSS

knowledge

author：focus 2025-09-29 12:25:55 Page View：338

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： NYU Langone launches private ChatGPT for its health care data
Next article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

explore

Guidelines to prevent youth baseball injuries need more muscle

Apitcheratthe2018LittleLeagueWorldSeries.RobCarr/GettyImages“Weallknowthatweareinthemiddleofanepidem

FDA panel gives mixed vote on blood pressure devices

AdobeAnadvisorypaneltotheFoodandDrugAdministrationdeliveredasplitdecisiononasurgicalsystemusedinacon

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

Australia’s approach to dialysis celebrates life

OSCARDELPOZO/AFPviaGettyImagesIn1972,asCongresspromiseddialysisandrehabilitationforallkidneyfailurep